Gilead Versus Merck - $200 Million? Was That It?
March 26, 2016 at 16:54 PM EDT
Gilead was ordered to pay $200MM to Merck in its HCV patent dispute. It seemed anti-climactic given the $2B Merck was seeking. Potential ongoing royalties to Merck could be problematic. The question remains, "Where will Gilead find new patients?"
